BTIG Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Thomas Shrader has initiated coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and a price target of $8.
October 03, 2023 | 8:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProMIS Neurosciences has received a Buy rating from BTIG with a price target of $8.
The Buy rating and price target of $8 announced by BTIG analyst Thomas Shrader is a positive signal for ProMIS Neurosciences. This could potentially attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100